Technology evaluation: Rexin-G, Epeius Biotechnologies.
Rexin-G is a 'pathotropic', tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene, under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. The therapy is currently undergoing phase I/II clinical trials.
Morse
Michael
M
Duke University Medical Center, Division of Medical Oncology, Box 3233 Room 3803, Red Zone, Duke South Clinics, Durham, NC 27710, USA. m.morse@cgct.duke.edu
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy; D056746:Cyclin G; D056766:Cyclin G1; D016213:Cyclins / Q000235:genetics* / Q000378:metabolism; D004247:DNA / Q000627:therapeutic use*; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D012190:Retroviridae
C534702:CCNG1 protein, human; C534703:Ccng1 protein, mouse; D056746:Cyclin G; D056766:Cyclin G1; D016213:Cyclins; D004247:DNA